Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3